267 related articles for article (PubMed ID: 18648350)
1. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses.
Otsuki A; Patel A; Kasai K; Suzuki M; Kurozumi K; Chiocca EA; Saeki Y
Mol Ther; 2008 Sep; 16(9):1546-55. PubMed ID: 18648350
[TBL] [Abstract][Full Text] [Related]
2. Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses.
Otsuki A; Patel A; Kasai K; Suzuki M; Kurozumi K; Antonio Chiocca E; Saeki Y
Mol Ther; 2008 Sep; 16(9):1546-1555. PubMed ID: 28189010
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase inhibitor valproic acid enhances equine herpesvirus type 1 (EHV-1)-mediated oncolysis of human glioma cells.
White MC; Frampton AR
Cancer Gene Ther; 2013 Feb; 20(2):88-93. PubMed ID: 23306611
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.
Nakashima H; Kaufmann JK; Wang PY; Nguyen T; Speranza MC; Kasai K; Okemoto K; Otsuki A; Nakano I; Fernandez S; Goins WF; Grandi P; Glorioso JC; Lawler S; Cripe TP; Chiocca EA
J Clin Invest; 2015 Nov; 125(11):4269-80. PubMed ID: 26524593
[TBL] [Abstract][Full Text] [Related]
5. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
6. Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
Jennings VA; Scott GB; Rose AMS; Scott KJ; Migneco G; Keller B; Reilly K; Donnelly O; Peach H; Dewar D; Harrington KJ; Pandha H; Samson A; Vile RG; Melcher AA; Errington-Mais F
Mol Ther; 2019 Jun; 27(6):1139-1152. PubMed ID: 31053413
[TBL] [Abstract][Full Text] [Related]
7. Active immunotherapy: oncolytic virus therapy using HSV-1.
Todo T
Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy.
Höti N; Chowdhury W; Hsieh JT; Sachs MD; Lupold SE; Rodriguez R
Mol Ther; 2006 Dec; 14(6):768-78. PubMed ID: 16990052
[TBL] [Abstract][Full Text] [Related]
9. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide.
Naito S; Obayashi S; Sumi T; Iwai S; Nakazawa M; Ikuta K; Yura Y
Cancer Gene Ther; 2006 Aug; 13(8):780-91. PubMed ID: 16645620
[TBL] [Abstract][Full Text] [Related]
11. The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells.
Berghauser Pont LM; Kleijn A; Kloezeman JJ; van den Bossche W; Kaufmann JK; de Vrij J; Leenstra S; Dirven CM; Lamfers ML
PLoS One; 2015; 10(5):e0127058. PubMed ID: 25993039
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
13. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
[TBL] [Abstract][Full Text] [Related]
14. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
Kambara H; Okano H; Chiocca EA; Saeki Y
Cancer Res; 2005 Apr; 65(7):2832-9. PubMed ID: 15805284
[TBL] [Abstract][Full Text] [Related]
15. Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma.
Kanai R; Tomita H; Hirose Y; Ohba S; Goldman S; Okano H; Kawase T; Yazaki T
Hum Gene Ther; 2007 Jan; 18(1):63-73. PubMed ID: 17238803
[TBL] [Abstract][Full Text] [Related]
16. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector.
McKee TD; Grandi P; Mok W; Alexandrakis G; Insin N; Zimmer JP; Bawendi MG; Boucher Y; Breakefield XO; Jain RK
Cancer Res; 2006 Mar; 66(5):2509-13. PubMed ID: 16510565
[TBL] [Abstract][Full Text] [Related]
17. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.
Ikeda K; Wakimoto H; Ichikawa T; Jhung S; Hochberg FH; Louis DN; Chiocca EA
J Virol; 2000 May; 74(10):4765-75. PubMed ID: 10775615
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice.
Reisoli E; Gambini E; Appolloni I; Gatta V; Barilari M; Menotti L; Malatesta P
Cancer Gene Ther; 2012 Nov; 19(11):788-95. PubMed ID: 22996742
[TBL] [Abstract][Full Text] [Related]
20. DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas.
Okemoto K; Kasai K; Wagner B; Haseley A; Meisen H; Bolyard C; Mo X; Wehr A; Lehman A; Fernandez S; Kaur B; Chiocca EA
Clin Cancer Res; 2013 Nov; 19(21):5952-9. PubMed ID: 24056786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
